ImmunoGen appoints Anna Berkenblit, MD, MMSc VP and CMO
ImmunoGen announced the appointment of Anna Berkenblit, MD, MMSc, as VP and CMO. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. April 01, 2015